BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 8962318)

  • 1. Clinical safety and tolerability of microemulsion cyclosporine in stable renal transplant patients.
    Gracida C; Melchor JL
    Transplant Proc; 1996 Dec; 28(6):3379. PubMed ID: 8962318
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of tolerability, safety, and efficacy of cyclosporine microemulsion in renal transplant recipients.
    Gracida C; Melchor JL; Miranda ME; Bartolano C
    Transplant Proc; 1996 Aug; 28(4):2171-3. PubMed ID: 8769191
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
    Offermann G; Korn A
    Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201
    [No Abstract]   [Full Text] [Related]  

  • 4. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
    Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
    Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
    Buchholz B; Korn A
    Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized, controlled, double-blind study of the safety and tolerability of Sandimmun Neoral in stable renal transplant patients. Argentine Multicentre Study Group.
    Massari PU; Grosso S; de Boccardo G; Vásquez MC; Schiavelli RO; Sabbatiello RR; Casadei DH; Rial MC; Jost LJ; Túrin MD; Agost Carreño C A; Maggiora EC; Gadea MM
    Transplant Proc; 1996 Dec; 28(6):3365-7. PubMed ID: 8962310
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and tolerability of Neoral in transplant recipients.
    Feutren G; Wong R; Jin J; Niese D; Mellein B
    Transplant Proc; 1996 Aug; 28(4):2177-82. PubMed ID: 8769193
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term results of conversion from existing to microemulsion formulation of cyclosporine.
    Neumayer HH; Färber L; Budde K; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J; Luft FC
    Transplant Proc; 1996 Aug; 28(4):2207-13. PubMed ID: 8769202
    [No Abstract]   [Full Text] [Related]  

  • 9. Conversion from regular cyclosporine to microemulsion cyclosporine following heart transplantation.
    Heroux AL; LeBlanc MH; Beaudoin D; Simard S; Coulombe DA; Gleeton O; Lemieux MD; Doyle DP
    Transplant Proc; 1996 Dec; 28(6):3145-8. PubMed ID: 8962219
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group.
    Barone G; Bunke CM; Choc MG; Hricik DE; Jin JH; Klein JB; Marsh CL; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplant Proc; 1996 Aug; 28(4):2183-6. PubMed ID: 8769194
    [No Abstract]   [Full Text] [Related]  

  • 11. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
    Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
    Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin in a porcine renal transplant model.
    Almond PS; Moss A; Nakhleh R; Melin M; Chen S; Salazar A; Shirabe K; Matas A
    Transplant Proc; 1993 Feb; 25(1 Pt 1):716. PubMed ID: 8438452
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical study of sandimmun neoral in cadaveric renal transplantation.
    Xue W; Chen Y; Xing J; Tian P
    Transplant Proc; 1996 Jun; 28(3):1333-4. PubMed ID: 8658682
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of Neoral and Sandimmune preparations in renal transplant patients--improved pharmacokinetics with neoral.
    Warrens AN; Salama A; Waters JB; Lechler RI
    Transplant Proc; 1996 Aug; 28(4):2169-70. PubMed ID: 8769190
    [No Abstract]   [Full Text] [Related]  

  • 15. Conversion from Sandimmune to Neoral in stable renal transplant recipients. Sandoz Study Group OLN-353.
    Pescovitz MD
    Transplant Proc; 1996 Aug; 28(4):2196-8. PubMed ID: 8769198
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of microemulsion form cyclosporine immediately after kidney transplantation without intravenous cyclosporine.
    Jirasiritham S; Sumethkul V; Mavichak V; Jirasiritham S
    Transplant Proc; 1998 Aug; 30(5):1760-1. PubMed ID: 9723270
    [No Abstract]   [Full Text] [Related]  

  • 17. Conversion of cyclosporine to azathroprine in renal transplant recipients.
    Bassiri A; Amiranssari B; Gol S
    Transplant Proc; 1995 Oct; 27(5):2691. PubMed ID: 7482877
    [No Abstract]   [Full Text] [Related]  

  • 18. Conversion from Sandimmune to Neoral in stable liver graft recipients.
    Pollard SG; Lodge JP
    Transplant Proc; 1996 Aug; 28(4):2244-6. PubMed ID: 8769213
    [No Abstract]   [Full Text] [Related]  

  • 19. Case reports on conversion to Neoral therapy in renal transplant patients.
    Curtis JJ
    Transplant Proc; 1996 Aug; 28(4):2221-2; discussion 2218. PubMed ID: 8769205
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of the new cyclosporine formulation, Consupren, in renal transplant patients.
    Stephan AG; Barbari A; Masri MA; Rizk S; Moubarak R; Frem GJ; Kamel G; Baracat-Khoury W; Karam A
    Transplant Proc; 1996 Jun; 28(3):1348-9. PubMed ID: 8658688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.